Bailard, Inc. Mersana Therapeutics, Inc. Transaction History

Bailard, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$8.56 - $14.47 $950,160 - $1.61 Million	-111,000 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$13.28 - $18.07 $265,600 - $361,400	-20,000 Reduced 15.27%	111,000 $1.51 Million
Q1 2021 May 13, 2021	SELL	$15.31 - $26.52 $643,020 - $1.11 Million	-42,000 Reduced 24.28%	131,000 $2.12 Million
Q3 2020 Nov 10, 2020	SELL	$16.2 - $25.7 $291,600 - $462,600	-18,000 Reduced 9.42%	173,000 $3.22 Million
Q2 2020 Aug 12, 2020	BUY	$5.24 - $23.4 $241,040 - $1.08 Million	46,000 Added 31.72%	191,000 $4.47 Million
Q1 2020 Apr 16, 2020	BUY	$4.41 - $9.28 $639,450 - $1.35 Million	145,000 New	145,000 $845,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.